|
|
|
|
| LEADER |
03380nam a22004815i 4500 |
| 001 |
978-1-4614-5380-2 |
| 003 |
DE-He213 |
| 005 |
20151204173804.0 |
| 007 |
cr nn 008mamaa |
| 008 |
130417s2013 xxu| s |||| 0|eng d |
| 020 |
|
|
|a 9781461453802
|9 978-1-4614-5380-2
|
| 024 |
7 |
|
|a 10.1007/978-1-4614-5380-2
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a QR180-189.5
|
| 072 |
|
7 |
|a MJCM
|2 bicssc
|
| 072 |
|
7 |
|a MED044000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.079
|2 23
|
| 245 |
1 |
0 |
|a Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines
|h [electronic resource] /
|c edited by Manmohan Singh.
|
| 264 |
|
1 |
|a Boston, MA :
|b Springer US :
|b Imprint: Springer,
|c 2013.
|
| 300 |
|
|
|a X, 370 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 505 |
0 |
|
|a Critical parameters that govern the optimization of vaccine formulations -- Development of Biophysical assays to better understand vaccine formulation stability -- Rational design of vaccine formulations -- Monitoring stability and efficacy of multi-valent vaccine formulations.- Overcoming challenges of multi component alum formulations.- Delivery of various TLR adjuvants using alum platform -- History of use of emulsions for vaccine delivery -- MF59 o/w emulsion : History and safety over the last 2 decades -- Optimizing novel nanoemulsions for delivery of next generation antigens and adjuvants -- Modulating vaccine responses with innate immunity : Use of PLGA nanoparticles for delivering multiple TLR agonists -- Shape matters : Role of nanoparticle shape in induction of immune responses to a vaccine. .
|
| 520 |
|
|
|a Development of new-generation vaccines is now more challenging than ever, as identifying, purifying and evaluating vaccine antigens is a complex undertaking. Most importantly, once the relevant antigens have been identified, key focus then shifts to the development of suitable delivery systems and formulations to achieve maximum in vivo potency with minimum potential side effects. These novel formulations—many of which will be nanoparticulates—can deliver the antigens to the desired site, to the relevant antigen presenting cells, and prevent systemic exposure of the immune potentiators. The proposed book will outline all the critical steps that need to be considered for successful development of various types of nanoparticulate delivery systems for vaccine antigens. These contributions from leading experts in the area of vaccine formulation and delivery systems will tie in what is the most current status, including clinical evaluations with these novel vaccine technologies.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Medical microbiology.
|
| 650 |
|
0 |
|a Vaccines.
|
| 650 |
|
0 |
|a Pharmaceutical technology.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Medical Microbiology.
|
| 650 |
2 |
4 |
|a Vaccine.
|
| 650 |
2 |
4 |
|a Pharmaceutical Sciences/Technology.
|
| 700 |
1 |
|
|a Singh, Manmohan.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9781461453796
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-1-4614-5380-2
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
